Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial.

MLA

Reddy, Amit K., et al. “Risk of Failing Both Methotrexate and Mycophenolate Mofetil from the First-Line Antimetabolites as Steroid-Sparing Treatment (FAST) Uveitis Trial.” Journal of Ophthalmic Inflammation and Infection, vol. 13, no. 1, June 2023, p. 29. EBSCOhost, https://doi.org/10.1186/s12348-023-00350-5.

APA

Reddy, A. K., Miller, D. C., Sura, A. A., Rathinam, S. R., Gonzales, J. A., Thundikandy, R., Kanakath, A., Murugan, B., Vedhanayaki, R., Lim, L. L., Suhler, E. B., Doan, T., Al-Dhibi, H. A., Goldstein, D. A., Arellanes-Garcia, L., & Acharya, N. R. (2023). Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial. Journal of Ophthalmic Inflammation and Infection, 13(1), 29. https://doi.org/10.1186/s12348-023-00350-5

Chicago

Reddy, Amit K, D Claire Miller, Amol A Sura, S R Rathinam, John A Gonzales, Radhika Thundikandy, Anuradha Kanakath, et al. 2023. “Risk of Failing Both Methotrexate and Mycophenolate Mofetil from the First-Line Antimetabolites as Steroid-Sparing Treatment (FAST) Uveitis Trial.” Journal of Ophthalmic Inflammation and Infection 13 (1): 29. doi:10.1186/s12348-023-00350-5.